Shorts NEWS LABORATORIES one-stop-shop, adapté à fois encore, les CROs structures and national and places them in des labos prêts à déléguer qui prendront le virage bridgeheads. And here I open competition with de nouvelles fonctions. de la data vont devoir would mention, amongst communication agencies. Une stratégie qui renforce composer avec une nouvelle others, CIToxLAB, ICTA, l’engagement des donneurs concurrence. Je pense bien Ascopharm or MultiHealth. Is digital revolution an d’ordres et qui les place évidemment aux start- These operators contribute advantage in this sector? en concurrence frontale ups et surtout aux géants of course to restoring the avec les agences de de l’informatique comme attractiveness of France in Rémi Vincente: communication. Google ou IBM. ■ the field of clinical trials. The digital revolution is the greatest challenge to be La révolution numérique Is France again a field of faced. More precisely, the est-elle un atout pour la choice for clinical trials? Still, the CROs are facing gap between the players profession ? profound structural changes... who will know how to Rémi Vincente: build on the healthcare Rémi Vincente : The Contract Research Rémi Vincente: data and those who La révolution numérique Organizations established One must not rejoice too won’t will increase. The est le plus grand défi à in France show an quickly. CROs must cope massive exploitation of relever. Plus précisément, extremely healthy picture with serious changes the epidemiological and l’écart va se creuser entre since 2015, according to that challenge their pharmaco-epidemiological les acteurs qui sauront a Xerfi France market adaptation capacity. data regarding the tirer parti de la profusion research about this sector. Certainly, suppliers have functioning of the healthcare des données de santé, et The turnover of our panel new opportunities along services or medical practices les autres. L’exploitation of CORs increased by with the breakthrough opens up a wide array of massive des données 8% in 2017, which is the of observational, post- possibilities in terms of épidémiologiques et third consecutive year authorization and medical research, innovation and pharmaco-épidémiologiques of growth. And, with device studies. Without industrial developments. sur le fonctionnement des 5% CAGR, the activity forgetting the progressive Nevertheless, developing ad services de santé ou les looks promising by 2020, opening of the medical hoc studies with patients pratiques médicales ouvre according to our forecasts. databases. But in order to recruited by health care de fait un vaste champ The structural drivers of the take advantage of these professionals will still des possibles en termes market remain favourable, opportunities, contract be a necessity. There is de recherche, d’innovation indeed. On the one hand, research companies will nothing better than mixed et de développements the R&D expenditure of have to develop new skills. studies when it comes to 17 industriels. Pour autant, pharmaceutical laboratories And this is where the shoe analysing the benefit/risk monter des études ad hoc and biotech companies will pinches. Compared to them, ratio of healthcare products avec des patients recrutés increase by 2.5% per year. the Big CROs from abroad in real life. The access to par des professionnels de On the other hand, the (such as IqVia, Syneos, health data will also be santé sera toujours une outsourcing strategies of Health or Parexel) have supported by the integration nécessité. Pour analyser laboratories will continue a clear head start. These of connected objects into a le ratio bénéfice/risque with the objectives of companies deploy ambitious medical context. In order to des produits de santé improving the cycle of drug acquisition policies in exploit the data provided dans la vraie vie, rien ne development and placement order to acquire new skills by connected objects, it will vaut en effet les études on the market. Generally, precisely. Thus, they are be necessary to develop mixtes. L’accès aux données this favourable position of gradually moving away from algorithms and, of course, de santé sera également France with principals is their CRO status towards to obtain patients’ consent alimenté par l’intégration explained by the revision of that of COOs (Contract to validate the results. des objets connectés dans the regulatory framework, Commercial Organizations). And once again, the CROs un contexte médical. Pour in particular the Jardé As such, they stand out that will take up the data exploiter les données des Law, or the creation as one-stop-shop entities challenge successfully objets connectés, il faudra of the unique hospital adapted to the laboratories will have to face the new développer des algorithmes convention. It is also that are ready to delegate competition. And here I et bien sûr obtenir l’aval explained by the suppliers’ new functions. A strategy refer to start-ups and, in des patients pour valider network reconstruction that strengthens the particular, to IT giants such les résultats. Et une around leading foreign commitment of principals as Google or IBM. ■ The Healthcare Packaging Products Magazine /Doses 712018 - April / May / June